Clinically, this is important because CDCP1 expression is often elevated in primary cancers and prognostic of poor outcome and survival [46]; however, recent evidence indicates its expression actually decreases within metastatic prostate cancer lesions (B. Knudsen, personal communication). This evidence concerns the gene CDCP1 and prostate carcinoma.